Fujian Cosunter's Novel Hepatitis B Drug GST-HG141 Completes Patient Enrollment for Phase III Trial
Stock News
Feb 04
Fujian Cosunter Pharmaceutical Co.,Ltd. (300436.SZ) has announced that its innovative drug subsidiary, Fujian Cosunter Zhonglin Biotechnology Co., Ltd., has successfully completed patient enrollment for the Phase III clinical trial of its Class 1 innovative hepatitis B treatment, Nairuikewei (GST-HG141). A total of 578 participants have been enrolled in the study.
Following the completion of patient enrollment for the GST-HG141 Phase III clinical trial, the study will proceed according to the established clinical protocol and requirements. The drug must subsequently receive marketing approval from the National Medical Products Administration before it can be launched commercially.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.